GE HealthCare Technologies (GEHC) FDA Approvals

GE HealthCare Technologies logo
$82.12 -1.54 (-1.84%)
As of 11:24 AM Eastern
This is a fair market value price provided by Massive. Learn more.

GE HealthCare Technologies' Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by GE HealthCare Technologies (GEHC). Over the past two years, GE HealthCare Technologies has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as mangaciclanol, Vizamyl, and Cerianna. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

Mangaciclanol FDA Regulatory Events

Mangaciclanol is a drug developed by GE HealthCare Technologies for the following indication: magnetic resonance imaging (MRI) contrast agent (MBCA). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Vizamyl FDA Regulatory Events

Vizamyl is a drug developed by GE HealthCare Technologies for the following indication: For beta-amyloid detection. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Cerianna FDA Regulatory Events

Cerianna is a drug developed by GE HealthCare Technologies for the following indication: For Lobular Breast Cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

GE HealthCare Technologies FDA Events - Frequently Asked Questions

In the past two years, GE HealthCare Technologies (GEHC) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, GE HealthCare Technologies (GEHC) has reported FDA regulatory activity for the following drugs: mangaciclanol, Vizamyl and Cerianna.

The most recent FDA-related event for GE HealthCare Technologies occurred on November 19, 2026, involving mangaciclanol. The update was categorized as "Results," with the company reporting: "GE HealthCare announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA)."

Current therapies from GE HealthCare Technologies in review with the FDA target conditions such as:

  • magnetic resonance imaging (MRI) contrast agent (MBCA) - mangaciclanol
  • For beta-amyloid detection. - Vizamyl
  • For Lobular Breast Cancer - Cerianna
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:GEHC last updated on 11/19/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners